The KrasG12D copy gain and associated upregulation of antioxidant capacity was also shown to drive malignant progression and metastatic potential in lung cancer cells and lung tumors in vivo, as the rate of tumor cell proliferation was reduced by treatment in vivo with a glutamate cysteine ligase (GCL) inhibitor (1-buthionine-S,R-sulfoximine (BSO)), which blocks GSH biosynthesis42. This evidence concerns the gene GCLC and lung carcinoma.